HMOX1 and peripheral arterial disease: Given that increased intramuscular lipids are a known pathological feature of PAD myopathy and contribute to oxidative stress [42,43,44,45,46], the reduced TFRC expression observed specifically in CLI muscle (despite elevated intramuscular HMOX1 in both IC and CLI patients) could represent an important biomarker of enhanced myopathic disease.